Peregrine Pharmaceuticals (NASDAQ:PPHM) will be issuing its quarterly earnings data before the market opens on Monday, December 11th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter.

Peregrine Pharmaceuticals (NASDAQ:PPHM) last released its quarterly earnings results on Monday, September 11th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.06. Peregrine Pharmaceuticals had a negative return on equity of 38.19% and a negative net margin of 23.15%. The firm had revenue of $27.08 million for the quarter, compared to analyst estimates of $15.22 million.

Shares of Peregrine Pharmaceuticals (PPHM) traded down $0.06 on Tuesday, hitting $5.14. The company’s stock had a trading volume of 117,100 shares, compared to its average volume of 310,554. Peregrine Pharmaceuticals has a one year low of $1.96 and a one year high of $5.78.

A number of equities analysts have issued reports on the company. Zacks Investment Research raised Peregrine Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 18th. ValuEngine lowered Peregrine Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday. Finally, Noble Financial started coverage on Peregrine Pharmaceuticals in a research report on Friday, September 29th. They set a “buy” rating and a $10.00 price target on the stock.

A hedge fund recently raised its stake in Peregrine Pharmaceuticals stock. Northern Trust Corp lifted its position in shares of Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) by 9.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 454,451 shares of the biopharmaceutical company’s stock after acquiring an additional 38,604 shares during the period. Northern Trust Corp owned about 1.01% of Peregrine Pharmaceuticals worth $276,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 18.88% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Peregrine Pharmaceuticals (PPHM) Set to Announce Earnings on Monday” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/12/05/peregrine-pharmaceuticals-pphm-set-to-announce-earnings-on-monday.html.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts.

Earnings History for Peregrine Pharmaceuticals (NASDAQ:PPHM)

Receive News & Ratings for Peregrine Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Peregrine Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.